A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes
Early-phase dose-finding clinical trials are often subject to the issue of late-onset outcomes. In phase I/II clinical trials, the issue becomes more intractable because toxicity and efficacy can be competing risk outcomes such that the occurrence of the first outcome will terminate the other one. I...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
John Wiley and Sons Inc
2021
|
Subjects: | |
Online Access: | View Fulltext in Publisher |